A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure
Xinli Li, Jian Zhang, Jun Huang, Aiqun Ma, Jiefu Yang, Weimin Li, Zonggui Wu, Chen Yao, Yuhui Zhang, Wenming Yao, Boli Zhang, Runlin Gao, Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group, Xinli Li, Jian Zhang, Jun Huang, Aiqun Ma, Jiefu Yang, Weimin Li, Zonggui Wu, Chen Yao, Yuhui Zhang, Wenming Yao, Boli Zhang, Runlin Gao, Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group
Abstract
Objectives: The purpose of this study was to assess the effects of qili qiangxin capsules in patients with chronic heart failure (CHF).
Background: Qili qiangxin capsules are a traditional Chinese medicine that has been approved in China for the treatment of CHF, but the evidence supporting its efficacy remains unclear.
Methods: A total of 512 patients with CHF were enrolled and randomly assigned to receive the placebo or qili qiangxin capsules in addition to their standard medications for the treatment of CHF. The primary endpoint was the reduction or percent change in the plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level during 12 weeks of treatment.
Results: At the 12-week follow-up, a significant reduction in the NT-proBNP level from baseline was observed in both groups, but the qili qiangxin capsule group demonstrated a significantly greater reduction than the placebo group (p = 0.002); 47.95% of patients in the qili qiangxin capsule group demonstrated reductions in NT-proBNP levels of at least 30% compared with 31.98% of patients in the placebo group (p < 0.001). Treatment with qili qiangxin capsules also demonstrated superior performance in comparison to the placebo with respect to New York Heart Association functional classification, left ventricular ejection fraction, 6-min walking distance, and quality of life.
Conclusions: On a background of standard treatment, qili qiangxin capsules further reduced the levels of NT-proBNP. Together, our data suggest that qili qiangxin capsules could be used in combination therapy for CHF.
Keywords: 6-min walking distance; 6MWD; CCE; CHF; LVEF; MLHFQ; Minnesota Living With Heart Failure Questionnaire; N-terminal pro–B-type natriuretic peptide; NT-proBNP; TCM; chronic heart failure; composite cardiac event(s); left ventricular ejection fraction; qili qiangxin capsules; randomized controlled trial; traditional Chinese medicine.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed